Diseases of protein conformation: What do in vitro experiments tell us about in vivo diseases?

Trends in Biochemical Sciences

Volumn 28, Issue 11, 2003, Pages 585-592

  Buxbaum, Joel N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; ATRIAL NATRIURETIC FACTOR; BETA 2 MICROGLOBULIN; CALCITONIN; CYSTATIN C; FIBRINOGEN; GELSOLIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INSULIN; LACTOFERRIN; LYSOZYME; PREALBUMIN; PRION PROTEIN; PROLACTIN; PROTEIN; RECOMBINANT PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; BRAIN SPONGIOSIS; CELL INCLUSION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MYELOMA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN PURIFICATION; REVIEW; THERMODYNAMICS; THYROID TUMOR; WILD TYPE;

ANIMALIA;

EID: 1542301571     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2003.09.009     Document Type: Article

References (62)

1. Westermark P., et al. Amyloid fibril protein nomenclature - 2002. Amyloid. 9:2002;197-200.
2. Buxbaum J.N., Tagoe C.E. The genetics of the amyloidoses. Annu. Rev. Med. 51:2000;543-569.
3. Ailles L., et al. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab. Invest. 69:1993;443-448.
4. Mori C., et al. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid. 9:2002;88-102.
5. Yagui K., et al. Formation of islet amyloid fibrils in β-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin. Eur. J. Endocrinol. 132:1995;487-496.
6. Janson J., et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U. S. A. 93:1996;7283-7288.
7. Buxbaum J., Gallo G. Nonamyloidotic monoclonal immunogloblin deposition disease. Hematol. Oncol. Clin. North Am. 13:1999;1235-1248.
8. Hofmann-Guiliane C., et al. Association light chain deposition disease (LCDD) and amyloidosis. One case. Pathol. Res. Pract. 180:1985;214-216.
9. Teng M.H., et al. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab. Invest. 81:2001;385-396.
10. Sousa M.M., et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159:2001;1993-2000.
11. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
12. Tsuchiya K., et al. Familial amyotrophic lateral sclerosis with onset in bulbar sign, benign clinical course, and Bunina bodies: a clinical, genetic, and pathological study of a Japanese family. Acta Neuropathol. (Berl.). 100:2000;603-607.
13. Spillantini M.G., et al. α-synuclein in Lewy bodies. Nature. 388:1997;839-840.
14. Parmar J.S., Lomas D.A. α-1-antitrypsin deficiency, the serpinopathies and conformational disease. J. R. Coll. Physicians Lond. 34:2000;295-300.
15. Nucifora F.C. Jr, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
16. Cohlberg J.A., et al. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry. 41:2002;1502-1511.
17. Fandrich M., et al. Amyloid fibrils from muscle myoglobin. Nature. 410:2001;165-166.
18. Chiti F., et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. U. S. A. 96:1999;3590-3594.
19. Bucciantini M., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
20. Levin M., et al. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J. Clin. Invest. 51:1972;2773-2776.
21. Eriksen N., et al. Mouse amyloid protein AA: homology with nonimmunoglobulin protein of human and monkey amyloid substance. Proc. Natl. Acad. Sci. U. S. A. 73:1976;964-967.
22. Stevens F.J. Four structural risk factors identify most fibril-forming κ light chains. Amyloid. 7:2000;200-211.
23. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120:1984;885-890.
24. Cohen D.H., et al. Amyloid fibril in hereditary cerebral hemorrhage with amyloidosis (HCHWA) is related to the gastroentero-pancreatic neuroendocrine protein, gamma trace. J. Exp. Med. 158:1983;623-628.
25. Maury C.P., et al. Finnish hereditary amyloidosis. Amino acid sequence homology between the amyloid fibril protein and human gelsolin. FEBS Lett. 260:1990;85-87.
26. Hammarstrom P., et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science. 299:2003;713-716.
27. Westermark P. The pathogenesis of amyloidosis: understanding general principles. Am. J. Pathol. 152:1998;1125-1127.
28. Jarrett J.T., Lansbury P.T. Jr. Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie. Cell. 73:1993;1055-1058.
29. Peterson S.A., et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 95:1998;12956-12960.
30. Lin Y.M., et al. Amyloid fibril formation in microwell plates for screening of inhibitors. Amyloid. 8:2001;182-193.
31. Reixach N., et al. Inhibition of β-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. J. Struct. Biol. 130:2000;247-258.
32. Dobson C.M. Getting out of shape. Nature. 418:2002;729-730.
33. Maury C.P.J., et al. Amyloid fibril formation in gelsolin-derived amyloidosis. Lab. Invest. 70:1994;558-564.
34. Gustavsson A., et al. Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem. Biophys. Res. Commun. 175:1991;1159-1164.
35. Westermark P., et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5036-5040.
36. Westermark G.T., et al. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem. Biophys. Res. Commun. 182:1992;27-33.
37. Gorevic P.D., et al. Ten to fourteen residue peptides of Alzheimer's disease fibril formation and its characteristic X-ray diffraction pattern. Biochem. Biophys. Res. Commun. 147:1987;854-862.
38. Gassett M., et al. Predicted α-helical region of the prion protein when synthesized as peptides form amyloid. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10940-10944.
39. Perlmutter D.H. Misfolded proteins in the endoplasmic reticulum. Lab. Invest. 79:1999;623-638.
40. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 110:2002;1389-1398.
41. Ron D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110:2002;1383-1388.
42. Hartl F.U., Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 295:2002;1852-1858.
43. Kopito R.R. ER quality control: the cytoplasmic connection. Cell. 88:1997;427-430.
44. Hershko A., et al. The ubiquitin system. Nat. Med. 6:2000;1073-1081.
45. Shringarpure R., et al. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J. Biol. Chem. 278:2003;311-318.
46. Auluck P.K., et al. Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 295:2002;865-868.
47. Kazemi-Esfarjani P., Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 287:2000;1837-1840.
48. Zoghbi H.Y., Botas J. Mouse and fly models of neurodegeneration. Trends Genet. 18:2002;463-471.
49. Fortini M.E., Bonini N.M. Modeling human neurodegenerative diseases in Drosophila: on a wing and a prayer. Trends Genet. 16:2000;161-167.
50. White J.T., Kelly J.W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13019-13024.
51. Miroy G.J., et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U. S. A. 93:1996;15051-15056.
52. Palha J.A., et al. Transthyretin regulates thyroid hormone levels in the choroid plexus, but not in the brain parenchyma: study in a transthyretin-null mouse model. Endocrinology. 141:2000;3267-3272.
53. Palha J.A., et al. Thyroid hormone metabolism in a transthyretin-null mouse strain. J. Biol. Chem. 269:1994;33135-33139.
54. Wei S., et al. Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. J. Biol. Chem. 270:1995;866-870.
55. Calero M., et al. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech. 50:2000;305-315.
56. Hatters D.M., et al. Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. Eur. J. Biochem. 269:2002;2789-2794.
57. DeMattos R.B., et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 99:2002;10843-10848.
58. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:1992;235-238.
59. Pepys M.B., et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5602-5606.
60. Serpell L.C., et al. The molecular basis of amyloidosis. Cell. Mol. Life Sci. 53:1997;871-887.
61. Zhang Y., et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13354-13359.
62. Pepys M.B., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417:2002;254-259.